Genetic variation predicting cisplatin cytotoxicity associated with overall survival in lung cancer patients receiving platinum-based chemotherapy.
about
Cancer pharmacogenomics: strategies and challengesSystems biology of cisplatin resistance: past, present and futureIn vitro human cell line models to predict clinical response to anticancer drugsPharmacogenomics of chemotherapeutic susceptibility and toxicityDexamethasone reduces sensitivity to cisplatin by blunting p53-dependent cellular senescence in non-small cell lung cancerIdentification of cisplatin-regulated metabolic pathways in pluripotent stem cellsA genome-wide association study for irinotecan-related severe toxicities in patients with advanced non-small-cell lung cancerPrediction of a time-to-event trait using genome wide SNP dataGenome-wide association and pharmacological profiling of 29 anticancer agents using lymphoblastoid cell linesCopper transporter CTR1 expression and tissue platinum concentration in non-small cell lung cancer.Meta-analysis on pharmacogenetics of platinum-based chemotherapy in non small cell lung cancer (NSCLC) patients.An integrated genomics approach identifies drivers of proliferation in luminal-subtype human breast cancer.EPS8 inhibition increases cisplatin sensitivity in lung cancer cells.DAPK3 suppresses acini morphogenesis and is required for mouse development.Genome-wide association studies in Africans and African Americans: expanding the framework of the genomics of human traits and disease.The clinicopathological significance of miR-1307 in chemotherapy resistant epithelial ovarian cancer.Genome-wide Association Study on Platinum-induced Hepatotoxicity in Non-Small Cell Lung Cancer Patients.Lymphoblastoid cell lines in pharmacogenomic discovery and clinical translationEstablishment & characterization of lymphoblastoid cell lines from patients with multiple primary neoplasms in the upper aero-digestive tract & healthy individuals.Predictive and prognostic molecular markers for cholangiocarcinoma in Han Chinese populationLocalization of association signal from risk and protective variants in sequencing studiesRelating human genetic variation to variation in drug responses.IL-6 signaling contributes to cisplatin resistance in non-small cell lung cancer via the up-regulation of anti-apoptotic and DNA repair associated moleculesIntegration of cell line and clinical trial genome-wide analyses supports a polygenic architecture of Paclitaxel-induced sensory peripheral neuropathy.MicroRNA-related genetic variants associated with clinical outcomes in early-stage non-small cell lung cancer patients.Computational discovery of transcription factors associated with drug response.Comprehensive genetic analysis of cytarabine sensitivity in a cell-based model identifies polymorphisms associated with outcome in AML patients.Germline polymorphisms in an enhancer of PSIP1 are associated with progression-free survival in epithelial ovarian cancerGenetic and epigenetic variants contributing to clofarabine cytotoxicity.Implications of genome-wide association studies in cancer therapeuticsThe P38α rs3804451 Variant Predicts Chemotherapy Response and Survival of Patients with Non-Small Cell Lung Cancer Treated with Platinum-Based Chemotherapy.Integrative gene set analysis: application to platinum pharmacogenomics.Genetic Variants Contributing to Colistin Cytotoxicity: Identification of TGIF1 and HOXD10 Using a Population Genomics Approach.Lymphoblastoid Cell lines: a Continuous in Vitro Source of Cells to Study Carcinogen Sensitivity and DNA RepairEvaluating the role of admixture in cancer therapy via in vitro drug response and multivariate genome-wide associations.Integrated analysis of DNA methylation and mRNA expression profiling reveals candidate genes associated with cisplatin resistance in non-small cell lung cancerGenome-Wide Association Studies for Idiosyncratic Drug-Induced Hepatotoxicity: Looking Back-Looking Forward to Next-Generation Innovation.Regulatory network changes between cell lines and their tissues of origin.Germline Genetic Variants and Lung Cancer Survival in African Americans.miR-206 regulates cisplatin resistance and EMT in human lung adenocarcinoma cells partly by targeting MET
P2860
Q24289309-10B24893-8C53-4403-8338-546F0A1CC55FQ26863585-5C1608A1-2E22-4BA4-8E59-9EBB09DCB2CBQ27000665-942C311E-2B84-4A3B-A71E-107F62E1F559Q27025558-B2D02BD6-76E9-4526-96A2-FDF702C35F6CQ28484432-F9EF40F3-8B19-44D5-B5E2-FAE5C8E4D90BQ28534469-12F47CB0-E3E9-4B6F-AA3D-F8DAA46509B4Q28943493-D7F2D79D-CE9B-4577-B4DD-D03D121E03A4Q30590346-39692458-57A1-4732-8D8B-B9E65744C4B7Q33746404-1935025E-277B-4A5A-887D-FD657618923CQ33875938-2B91E798-F7D6-4BEF-A2FB-D8AC18E5C654Q34325669-B757519C-09BF-42E4-BA0E-EE2B621D3F5CQ34989075-F46E30D9-AD19-414D-8600-B6F69B21F99CQ35075274-1FA998CA-EF53-48B0-AF3F-5537730697DAQ35108916-A6B57043-2F26-4900-BB49-705B672945DCQ35565624-ACE6D992-948B-4ED8-B87D-CB0008FF26F6Q35666862-FAFC7AF5-0FEE-47D6-B230-FBA98E07A0C0Q35769777-65BD0796-6C6A-4B32-9486-E53D186C8EB3Q35799841-0FD3761A-950B-4414-B8DF-2FACC5C5C7E4Q36134466-3FAF4CB0-A518-408C-8691-27DA9596AE3BQ36183219-6E447D6E-B87B-4A55-9DA1-E16568BC90C7Q36210698-9EB3DB53-CFD1-4900-B782-EBC4A542B853Q36252524-251350FE-09D4-4931-A21B-E08565BD2401Q36413863-B4E90DC8-6B1B-4DC6-B94D-9516CA00DA88Q36545157-079EF57C-E798-4907-87B2-1FD027AF2931Q36698880-E2BD5B43-B0CF-47AB-8C8A-815EB0DC6B69Q36844885-06A4199B-CE79-4160-8EE3-BC0E33D439FBQ36873301-5516425F-5EB1-4304-8B3F-B7B44FD81367Q36916243-FC7F4DA5-90DC-4109-A43D-57E14C5584BFQ37153800-EB4BBFCA-6923-4A71-852B-CF9DA1AEB52CQ37161892-2B98B06C-D720-4179-B5FE-73B102D6CB14Q37414070-7974D85C-59CF-4392-B6ED-739CCA0B42B2Q37519400-5348589B-46D6-4DE3-ADA0-522E3E0ABA85Q37729344-677F2180-C7DF-420C-8DDF-E87BA4760DC0Q38189401-D9A146F8-E302-48E1-B5C5-8767023368A5Q38840322-2654249A-8FC7-4D9F-AB20-6945AE243AD8Q39008172-EB4F53A4-C1D1-45D0-B3E4-D83C1E66E99BQ39158128-D2719A1A-CF11-4522-94CB-1C5F8588045CQ40045181-44FC3E2F-530C-4E0D-B991-08A4C50A4A99Q40158003-DE60D6B3-FCA9-446E-8C2F-7F71233A7362Q41134348-CF20D539-3FB8-49E5-8716-557D7C765190
P2860
Genetic variation predicting cisplatin cytotoxicity associated with overall survival in lung cancer patients receiving platinum-based chemotherapy.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Genetic variation predicting c ...... g platinum-based chemotherapy.
@ast
Genetic variation predicting c ...... g platinum-based chemotherapy.
@en
type
label
Genetic variation predicting c ...... g platinum-based chemotherapy.
@ast
Genetic variation predicting c ...... g platinum-based chemotherapy.
@en
prefLabel
Genetic variation predicting c ...... g platinum-based chemotherapy.
@ast
Genetic variation predicting c ...... g platinum-based chemotherapy.
@en
P2093
P2860
P1476
Genetic variation predicting c ...... g platinum-based chemotherapy.
@en
P2093
Ann M Moyer
Anthony J Batzler
Brooke L Fridley
Daniel J Schaid
Gregory D Jenkins
Liewei Wang
Nifang Niu
Ryan P Abo
P2860
P304
P356
10.1158/1078-0432.CCR-11-1133
P407
P577
2011-07-20T00:00:00Z